Empowering New Zealand Nurses for Excellence in Healthcare
Bicultural Structure
Membership includes belonging to a bicultural organisation focused on professional nursing issues and community health.
Insurance Coverage
Members receive up to $1 million indemnity insurance in New Zealand (not applicable for retired members). (Conditions apply).
Access to Publications
Members have access to the ‘Nursing Praxis in Aotearoa New Zealand’ journal.
Influence and Networking
Members contribute to a significant influencer in health policy decision-making and join a dynamic network of professional nurses committed to high standards of practice.
2 June 2026
Nurse Practitioner - North Shore, Auckland
Nurse Practitioner – North Shore, Auckland No weekends | Flexible hours | Supportive team Join a well‑established general practice on Auckland’s North Shore. Work in a friendly, collaborative environment with excellent work–life balance. The Role Provide patient-centred care across acute, chronic, and preventive health needs in a supportive primary care setting. What We Offer No weekends or public holidaysFlexible hours. Established patient baseSupportive clinical and admin teamModern...
2 June 2026
Registered Nurse - Auckland
Te Wairua (co-existing disorders – addictions + mental health) residential service in Royal Oak, great benefits and competitive salary package! Mon-Fri $78,020 - $86,174 salary (depending on experience) $7,000 annual position allowance + free meals + 22 days annual leave Monday to Friday, no evenings, no weekends! Registered Nurse – Te Wairua Royal Oak If you would like to make a positive difference and use your experience as a registered nurse, then join our Te Wairua (co-existing...
2 June 2026
New medicine supply notices
Colestyramine (Mylan) (Pharmacode: 2662000) Supplies may be limited from late May until July 2026. An alternative (Pharmacode: 2700026) was funded from 1 June and should be available from Orspec in early June. Kisqali (ribociclib): Storage changes Kisqali will once again be able to be stored at room temperature. More details and a flyer for patients are available on our website. Neocate Gold: Funding issue The Pharmacode for new look Neocate Gold was funded from 1 June. Oestradiol valerate...
1 June 2026
Ministry of Health - Medical Products & Natural Health Products Update
Welcome to the latest update from the Ministry of Health | Manatū Hauora on the regulation of medicines, medical devices and natural health products. This edition provides information on the Government’s recent decision to regulate sunscreens and other policy matters under the Medical Products Bill (the Bill). This update also accompanies the proactive release of documents relating to those decisions. This newsletter contains information on the following: New policy decisions for the Bill · ...
29 May 2026
Supply Issue – Risperidone (Teva) 0.5mg tablets and Risperidone (Teva) 2mg tablets
There is currently a supply disruption affecting risperidone (Teva) 0.5 mg and 2 mg tablets. This is due to an issue at the manufacturer. To support continuity of care, from 1 June, Pharmac will list (fund) alternative products, Risperidone Sandoz 0.5 mg tab and Risperidone Sandoz 2 mg tab. Please note Risperidone Sandoz tablets are not Medsafe‑approved and must therefore be prescribed and supplied in accordance with Section 29A of the Medicines Act. Further information about this...
29 May 2026
Supply disruption: Colestyramine Powder for Oral Suspension (Sachet)
Re: Supply disruption: Colestyramine Powder for Oral Suspension (Sachet). There is a supply disruption affecting the currently listed Section 29 colestyramine oral sachets, Colestyramine – Mylan. From 1 June, Pharmac will list an alternative Section 29 product: Questran Light (Neon). This is not a Medsafe‑approved product and must be prescribed in accordance with Section 29 of the Medicines Act. As no Medsafe approved product is currently listed on the Schedule, Section 29A does not...
29 May 2026
Pharmac Update: Primary Care Prescribers | 29 May 2026
Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 29 May 2026. It includes information on: New updates Resolved Supply Issues Supply Constraint – TruSteel Infusion Sets There is a global supply constraint affecting TruSteel infusion sets due to issues at a component supplier. This disruption is not specific to New Zealand and is likely to continue for the rest of 2026. It affects all four funded TruSteel infusion...
29 May 2026
Ministry of Health Library - Health Improvemtn & Innovation Digest
Issue 343 - 28 May 2026 Welcome to the fortnightly Health Improvement and Innovation Digest. The Digest has links to key evidence of interest, with access to new content arranged by topic. You can forward this newsletter to others who may be interested in receiving it. They can register and subscribe here. You can also access other recent issues of the digest here. If you have any queries, please email us at library@health.govt.nz. Article Access For articles that aren't open access, contact...
29 May 2026
Lowering LDL to <1.4 mmol/L reduces events in known CVD
Evidence from randomised trials on optimal LDL cholesterol targets for secondary prevention in known atherosclerotic cardiovascular disease is limited. In an open trial, 3048 patients with known CVD disease were randomised to an LDL target of below 1.4 mmol/L or below 1.8 mmol/L.1 The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction or stroke, revascularisation, or hospitalisation for unstable angina over 3 years. The median achieved LDL levels were 1.4...
29 May 2026
Pharmac Consultation
We’re writing to let you know that Pharmac is extending the consultation period on the proposed changes to access criteria for type 2 diabetes medicines. In May, we released a proposal to amend the Special Authority criteria for empagliflozin, liraglutide, and dulaglutide. We’ve received a significant amount of feedback so far, which reflects how important access to these medicines is for people living with type 2 diabetes. We’ve also heard that more people would like the opportunity to...
25 May 2026
New medicine supply notices
New medicine supply notices Fluorouracil inj 50 mg/ml 20 ml and 50 ml vials: (Pharmacodes: 2618435 and 2674092) Accord is out of stock of these products. Paracetamol oral liquid: Lower strength (120 mg per 5 ml)The brand of this product is changing brand from 1 June 2026. Updated medicine supply notices Droperidol inj 2.5 mg per ml, 1 ml ampoule (Pharmacode 2690543) The previously funded brand, PanPharma (Pharmacode:2527138), has been re-listed. There is a small amount of this stock...
25 May 2026
DATE CORRECTION - Testosterone (Reandron) Injection
This is to correct the dates sent out on Friday. Gonadron brand will be listed 1 July 2026 Brand change: We are writing to inform you of a brand change for testosterone undecanoate inj 250 mg per ml, (Reandron) Key Dates: The Gonadron brand of testosterone undecanoate inj 250 mg per ml is to be listed (funded) from 1 July 2026 on the Community Schedule and in Health NZ hospitals. Testosterone undecanoate inj 250 mg per ml (Reandron) brand will be delisted (no longer funded) 1 December...
24 May 2026
Pharmac Update: Primary Care Prescribers | 22 May 2026
Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 22 May 2026. It includes information on: New updates Resolved Supply Issues Supply Disruption - Ezetimibe with Simvastatin 10/80 mg (Zimybe) Due to a delay at the manufacturing site, there is a supply issue affecting ezetimibe with simvastatin 10/80 mg combination tablet (Zimybe). From 1 June 2026 Pharmac is funding an alternative product ezetimibe with simvastatin...
24 May 2026
Brand Change: testosterone undecanoate inj 250 mg per ml, (Reandron) to new brand (Gonadron)
Brand change: We are writing to inform you of a brand change for testosterone undecanoate inj 250 mg per ml, (Reandron) Key Dates: The Gonadron brand of testosterone undecanoate inj 250 mg per ml is to be listed (funded) from 1 June 2026 on the Community Schedule and in Health NZ hospitals. Testosterone undecanoate inj 250 mg per ml (Reandron) brand will be delisted (no longer funded) 1 November 2026. The active ingredients and excipients are the same as the Reandron brand. For more...
23 May 2026
Nurse Practitioner – Part-TimeOcean Breeze Health | Silverdale, Hibiscus Coast
Nurse Practitioner – Part-TimeOcean Breeze Health | Silverdale, Hibiscus Coast Ocean Breeze Health is a small, family-focused general practice located in beautiful Silverdale on the Hibiscus Coast. Due to the continued growth of our clinic, we are looking for a compassionate and patient-focused Nurse Practitioner to join our supportive team. This role will initially be approximately 16 hours per weekdays and hours negotiable and one Saturday morning (9-1pm ) per month. We are seeking someone...
23 May 2026
Pāhake Whaiora: Mental Health Services for Older People (MHSOP) Clinician - Taranaki
Māu te tono, nō mātou te whiwhi! (We would be honoured if you apply) 1.0 FTE (40 hours a week) Permanent position Location: Taranaki Mō te tūranga - About the role Join our team as a Pāhake Whaiora: Mental Health Services for Older People (MHSOP) Clinician and make a real difference in the lives of older people across Taranaki. In this role, you'll provide advanced assessment, clinical care, and coordination for Pāhake experiencing complex mental health, addiction, and cognitive health needs....
21 May 2026
Pharmac Consultation
Kia ora Pharmac is seeking feedback on a proposal to change brands of meningococcal ACWY, pneumococcal, and influenza vaccines – and widen access to the flu vaccine for all children from 6 months up to 5 years (6-59 months inclusive). We are also proposing to widen access to a vaccine to help prevent people who have already had a serious pneumococcal infection from getting it again. In August 2025, we released a Request for Proposals (RFP) for the supply of funded vaccines, excluding the...
21 May 2026
Supply Disruption - Ezetimibe with Simvastatin 10/80 mg (Zimybe)
Kia ora, RE: Supply Disruption - Ezetimibe with Simvastatin 10/80 mg combination tablet (Zimybe) Due to a delay at the manufacturing site, there is a supply issue affecting Ezetimibe with Simvastatin 10/80 mg (Zimybe). From 1 June 2026 Pharmac will fund an alternative product Ezetimibe with Simvastatin 10/80 mg (Vytorin). This is not a Medsafe approved product and should be prescribed and supplied in line with Section 29A of the Medicines Act. Further information, including resupply time...
20 May 2026
Extended Pharmacy Services
Health New Zealand and Pharmac have made the decision to extend pharmacy services. This decision means community pharmacies will be able to provide a wider range of funded clinical services for common conditions that may have otherwise required a GP visit, including: scabies treatment for children/families oral rehydration treatment for children headlice treatment for children/families pain and fever management for children conjunctivitis treatment for children treatment for...
Areas of interest
